Maravai director granted 46,293 restricted units

DeFord John A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

DeFord John A reported acquisition or exercise transactions in this Form 4 filing.

MARAVAI LIFESCIENCES HOLDINGS, INC. director John A. DeFord reported an award of 46,293 shares of Class A Common Stock in the form of restricted stock units. These RSUs were granted on May 26, 2026 under the company’s 2020 Omnibus Incentive Plan and vest in full on the earlier of one year from grant or the 2027 annual meeting of stockholders. Following this grant, DeFord directly holds 205,478 shares of Class A Common Stock.

Insider Trade Summary

Grant/Award: 46,293 shares

Grant/Award 1 txn

Insider DeFord John A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	46,293	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 205,478 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Figures

RSU grant size: 46,293 shares Holdings after transaction: 205,478 shares Grant price per share: $0.0000 per share

3 metrics

RSU grant size 46,293 shares Restricted stock units of Class A Common Stock granted May 26, 2026

Holdings after transaction 205,478 shares Class A Common Stock directly owned by John A. DeFord after grant

Grant price per share $0.0000 per share Reported transaction price per share for the RSU award

Key Terms

restricted stock units, 2020 Omnibus Incentive Plan, annual meeting of stockholders, Class A Common Stock

4 terms

restricted stock units financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Omnibus Incentive Plan financial

"restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus"

annual meeting of stockholders financial

"vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai"

Class A Common Stock financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MRVI director John A. DeFord report?

John A. DeFord reported receiving 46,293 restricted stock units of Maravai Class A Common Stock. The award is a compensation grant, not a market purchase, and increased his direct holdings to 205,478 shares after the transaction.

How many Maravai (MRVI) shares does John A. DeFord hold after this grant?

After the reported restricted stock unit grant, John A. DeFord directly holds 205,478 shares of Maravai Class A Common Stock. This figure reflects his updated ownership position immediately following the 46,293-share RSU award.

What type of equity was granted to John A. DeFord by Maravai (MRVI)?

Maravai granted John A. DeFord 46,293 restricted stock units representing Class A Common Stock. Restricted stock units are share-based compensation that convert into actual shares when vesting conditions are satisfied, aligning director incentives with shareholders.

When do John A. DeFord’s newly granted Maravai (MRVI) RSUs vest?

The 46,293 restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the date of Maravai’s 2027 annual meeting of stockholders. Once vested, the RSUs convert into shares of Class A Common Stock.

Was John A. DeFord’s Maravai (MRVI) transaction a stock purchase or a grant?

The transaction was a grant of 46,293 restricted stock units, not an open-market stock purchase. It represents equity compensation awarded under Maravai’s 2020 Omnibus Incentive Plan and was reported with transaction code “A” for grant or award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 06:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeFord John A

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		A		46,293(1)	A	$0	205,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for John DeFord	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)